8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 9, 2026·SEC
Material company update
Mar 20, 2026·SEC
AN2 Therapeutics, Inc.(ANTX)Earnings, Financials & Key Ratios
ANTX•NASDAQ
$5.11
Price updated Jun 27, 2026
AboutAN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.Show more
- Revenue$0
- EBITDA-$38M
- Net Income-$35M+31.5%
- EPS (Diluted)-1.16+32.6%
- ROE-52.14%-4.9%
ANTX Price & Volume
AN2 Therapeutics, Inc. (ANTX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Stage Burn Threatens Future Operational Continuity
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical and liquidity insolvency
"AN2 Therapeutics remains a pre-commercial biotechnology firm with zero revenue, leaving its valuation entirely dependent on the success of its boron-chemistry pipeline for non-tuberculous mycobacterial lung disease. The company faces significant liquidity risks as its cash position has dwindled to $19.9 million as of 2025Q4, necessitating potential dilutive capital raises to sustain ongoing clinical trials. Investors should monitor the firm's ability to manage its high R&D expenditure, which reached $14.7 million in 2024Q1, against its rapidly eroding asset base."
Verdict Logic
the company's cash position of $19.9 million as of 2025Q4 appears insufficient to support long-term clinical development without further dilutive financing.
ANTX Growth Metrics
AN2 Therapeutics, Inc. (ANTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.81%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM27.15%
Return on Capital
10 Years-146.98%
5 Years-58.59%
3 Years-57.51%
Last Year-56.42%
ANTX Recent Earnings
AN2 Therapeutics, Inc. (ANTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.29-26.1%
$0.23
Rev
—
—
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$0.29-20.8%
$0.24
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.31-34.8%
$0.23
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.21+32.3%
$0.31
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.29vs $0.23-26.1% | — |
| Q2 2026 | Mar 17, 2026 | $0.29vs $0.24-20.8% | — |
| Q4 2025 | Nov 12, 2025 | $0.31vs $0.23-34.8% | — |
| Q3 2025 | Aug 12, 2025 | $0.21vs $0.31+32.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for AN2 Therapeutics, Inc. (ANTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.11 | $140.02M | -4.41 | — | — | -52.14% | — | |
| $103.38 | $22.41B | -16.13 | 66.73% | -144.44% | -130.11% | — | |
| $2.26 | $130.86M | 15.07 | 24.27% | 27.82% | 35.58% | — | |
| $327.79 | $9.47B | -24.32 | -100% | — | -43.02% | — | |
| $14.00 | $325.03M | -3.65 | -3.42% | -89.56% | -64.04% | — | |
| $36.74 | $3.23B | -28.70 | 3024.43% | -62.17% | -13.96% | — |
Compare ANTX vs Peers
AN2 Therapeutics, Inc. (ANTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANTX SEC Filings & Documents
AN2 Therapeutics, Inc. (ANTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ANTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANTX Frequently Asked Questions
AN2 Therapeutics, Inc. (ANTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is ANTX profitable?
AN2 Therapeutics, Inc. (ANTX) reported a net loss of $34.6M for fiscal year 2025.
Dividend & Returns
What is ANTX's return on equity?
AN2 Therapeutics, Inc. (ANTX) has a return on equity (ROE) of -52.1%. Negative ROE indicates the company is unprofitable.
What is AN2 Therapeutics, Inc.'s free cash flow?
AN2 Therapeutics, Inc. (ANTX) had negative free cash flow of $31.3M in fiscal year 2025, likely due to heavy capital investments.